COVID-19 UPDATE

At GW Pharmaceuticals, we remain committed to ensuring our patients, healthcare partners and employees are supported during these challenging times. We are actively monitoring our supply chain and taking steps to help ensure continued supply of our products to patients. We will continue to monitor the COVID-19 situation and take steps to ensure that access and assistance for patients and healthcare partners remain consistent. If you wish to discuss more specific details please contact GW Pharmaceuticals via phone on +44 (0) 1223 238170 or via email at medinfo@gwpharm.com.

If you are reporting an Adverse Event and / or a Product Complaint, and you receive a network busy signal (i.e. if all lines are busy or engaged) please continue to try your call throughout the day or, preferably report via the above email address.

Douglas Snyder

Chief Legal Officer

Douglas Snyder has served as GW Pharmaceuticals Chief Legal Officer since July 2017. He brings more than 20 years of experience providing counsel in the pharmaceutical industry, at the Food and Drug Administration (FDA) and in private practice. Prior to joining GW, Doug led the legal and compliance teams as Senior Vice President, General Counsel, and Secretary for Actelion US. Prior to that, Doug held the position of Senior Vice President, General Counsel, Secretary at Eisai Inc. where he led the Legal, Compliance, Legislative Affairs, Internal Audit and Security Group.

From 1999-2005, Doug was Vice-President, Associate General Counsel for GlaxoSmithKline. During his tenure at GSK, Doug managed the legal and communications strategies related to some of the company’s most high profile matters concerning the New York Attorney General, the U.S. department of Justice and the FDA.

Before joining the pharmaceutical industry, Doug held the role of Associate General Counsel for the FDA where he counseled the Commissioner, appeared before Congress in key initiatives, and led the initial False Claims/Kickback cases against the pharmaceutical industry.